Webinar: The Supreme Court's "Pay-for-Delay" Decision in Actavis - What Now for Patent Settlements? | Practical Law

Webinar: The Supreme Court's "Pay-for-Delay" Decision in Actavis - What Now for Patent Settlements? | Practical Law

On June 27, 2013, Practical Law Company and McDermott Will & Emery LLP presented The Supreme Court's "Pay-for-Delay" Decision in Actavis - What Now for Patent Settlements?, a webinar on the Supreme Court's decision in F.T.C. v. Actavis, Inc., setting out the antitrust analysis of reverse payment settlements. Reverse payments have been used to settle certain patent infringement cases between the holder of a branded drug patent and a generic drug manufacturer. These settlements are commonly referred to as pay-for-delay agreements. Partners Jeffrey W. Brennan and William Gaede and Senior Counsel Glenn Engelmann, all with McDermott Will & Emery, discussed the antitrust and patent law aspects of the Actavis decision and analyzed its potential implications on reverse payment settlements and generic drug challenges to branded drug patents.

Webinar: The Supreme Court's "Pay-for-Delay" Decision in Actavis - What Now for Patent Settlements?

by PLC Antitrust
Law stated as of 27 Jun 2013 • USA (National/Federal)
On June 27, 2013, Practical Law Company and McDermott Will & Emery LLP presented The Supreme Court's "Pay-for-Delay" Decision in Actavis - What Now for Patent Settlements?, a webinar on the Supreme Court's decision in F.T.C. v. Actavis, Inc., setting out the antitrust analysis of reverse payment settlements. Reverse payments have been used to settle certain patent infringement cases between the holder of a branded drug patent and a generic drug manufacturer. These settlements are commonly referred to as pay-for-delay agreements. Partners Jeffrey W. Brennan and William Gaede and Senior Counsel Glenn Engelmann, all with McDermott Will & Emery, discussed the antitrust and patent law aspects of the Actavis decision and analyzed its potential implications on reverse payment settlements and generic drug challenges to branded drug patents.
Access the recorded webinar here (registration required to view recorded webinar).
Click here to download the webinar slides.